Fig. 3
From: NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis
NEDD4 promotes BC progression. a The proportion of ANT, DCIS, IDC, and BCLNM tissues showing NEDD4-positive staining is presented. NEDD4-positive expression was more frequent with tumor progression (χ2 test). b The median IRS was significantly increased in ANT, DCIS, IDC, and BCLNM tumors (Mann–Whitney test). c Representative IHC images of ANT, DCIS, IDC, and BCLNM are presented. The staining intensity appears higher in invasive lesions. d The median IRS is higher in IDC compared with DCIS of the same ER status (Mann–Whitney test). e Staining showing that NEDD4 expression is stronger in IDC than that in DCIS in the same tumor sample (*DCIS area, #IDC area). f The proportions of TNM stages I, II, and III showing NEDD4-positive staining are presented. NEDD4-positive expression is more frequent with TNM stage (χ2 test). g The median IRS significantly increased with TNM stages I, II, and III (Mann–Whitney test). h Representative IHC images of stages I, II, and III are presented. NEDD4, neural precursor cell-expressed developmentally downregulated gene 4; ANT, adjacent normal tissue; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; BCLNM, breast cancer with lymph node metastasis; IRS, immunoreactive score; IHC, immunohistochemistry; TNM, tumor–node–metastasis; ER, estrogen receptor